Thymosin β4 administration enhances fracture healing in mice.
Level 5 - mechanism / opinion, no new human data
Animal research (in vivo mouse study)
PubMed 25042765 · doi:10.1002/jor.22686
What was done
Mice underwent bilateral fibular osteotomy and received intraperitoneal injections of either thymosin β4 (Tβ4, 6 mg/kg) or saline. Fracture calluses were evaluated for biomechanical properties (peak force to failure, stiffness) and tissue composition using micro-computed tomography (µCT) and histomorphometry at 21 days post-fracture.
What was found
Compared to saline controls, Tβ4-treated calluses showed: - A 41% increase in peak force to failure (p < 0.01) and approximately 25% greater stiffness (p < 0.05). - Increased fractional volume of new mineralized tissue (18% greater, p < 0.01) and new highly mineralized tissue (26% greater, p < 0.05) by µCT. - Calluses that were nearly 23% smaller in total size (p < 0.05), with nearly 47% less old cortical bone (p < 0.05) and a 31% increase in new trabecular bone area per total callus area fraction (p < 0.05) by histomorphometry.
Why it matters
These findings suggest that systemic administration of the regenerative peptide thymosin β4 can accelerate fracture consolidation and enhance mechanical strength during bone healing in a rodent model.
Limits
The study is restricted to an animal model (mice) with a single fracture type (fibular osteotomy), so translational efficacy and safety in human fracture repair remain unproven. Total sample size (n), dosing duration/frequency, and long-term remodeling beyond 21 days were not specified in the abstract.
Cited by
- partial TB-500 promotes tissue recovery and bone regeneration.